Skip to main content

Table 1 Baseline characteristics of enrolled patients.

From: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial

Characteristic

Treatment arm

Number of patients randomized

CQ (n = 268)

DP (n = 268)

P

Gender: Male/Female (ratio)

126/142 (0.89)

132/136 (0.97)

0.60

Age, median years (range)

11 (0.25 -71)

12 (1 - 70)

0.38

Age Groups:

  

0.18

   <5 years

43 (16.0)

30 (11.2)

 

   5 -14 years

130 (48.5)

128 (47.8)

 

   >14 years

95 (35.5)

110 (41.0)

 

Location:

  

0.61

   Jalalabad

154 (57.5)

160 (59.7)

 

   Taloqan

58 (21.6)

61 (22.8)

 

   Maimana

56 (20.9)

47 (17.5)

 

Weight, median kg (range)

30 (5-93)

33 (7-89)

0.69

Geometric mean parasitaemia/μL (95% CI)

3339 (3000-3716)

3236 (2940 -3560)

0.67

Number with gametocytes

218 (81.3)

203 (75.2)

0.12

Haemoglobin concentration, mean g/dl (SD)

10.9 (1.46)

10.9 (1.42)

0.99

Anaemia (haemoglobin concentration < 10 g/dl)

49 (18.4)

44 (16.5)

0.35

Median white blood cells ×109/ml, median (range)

6.0 (3.6-54)

6.6 (3.0-12.4)

0.02

Body temperature °C, mean (95% CI)

37.3 (37.2-37.4)

37.3 (37.2-37.4)

0.77

Median systolic blood pressure, mmHg (range)

100 (80-160)

100 (80-170)

0.43

Median diastolic blood pressure, mmHg (range)

70 (50-100)

70 (50-100)

0.38

Median pulse rate, beat/min (range)

88 (60-140)

88 (60-140)

0.53

Jaundice

30 (11.3)

32 (12.1)

0.79

History of convulsions in last 24 hours

1 (0.37)

1 (0.37)

 
  1. Data for chloroquine (CQ) and dihydroartemisinin-piperaquine (DP) are number (%) unless otherwise indicated.